Search research articles
Contact Us
Filters
Showing results (871-880 of 962) with videos related to
Page
of 97
Sort By:
Circulation. Cardiovascular Quality and Outcomes
|
August 9, 2020
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events
Hironori Hara, David van Klaveren, Kuniaki Takahashi, et al.
American Heart Journal
|
March 8, 2024
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial
Mitchell Krucoff, Alessandro Spirito, Usman Baber, et al.
Archives of Cardiovascular Diseases
|
May 31, 2024
Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) study
Alexandre Gautier, Nicolas Danchin, Gregory Ducrocq, et al.
Lancet (London, England)
|
September 7, 2010
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
Shamir R Mehta, Jean-Francois Tanguay, John W Eikelboom, et al.
European Journal of Preventive Cardiology
|
July 6, 2023
Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease
Pascal M Burger, Jannick A N Dorresteijn, Aernoud T L Fiolet, et al.
The American Journal of Cardiology
|
October 26, 2019
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)
Chun Chin Chang, Ernest Spitzer, Ply Chichareon, et al.
The Lancet. Diabetes & Endocrinology
|
July 6, 2019
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K Ray, Helen M Colhoun, Michael Szarek, et al.
Journal of the American College of Cardiology
|
September 3, 2025
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants
Sean J Jurgens, Giorgio E M Melloni, Shinwan Kany, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 27, 2019
Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial
Mariusz Tomaniak, Ply Chichareon, Kuniaki Takahashi, et al.
BMJ Open
|
March 11, 2019
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)
Sergio Leonardi, Anna Franzone, Raffaele Piccolo, et al.
Page
of 97
Search research articles
Search
Showing results (871-880 of 962) with videos related to
Sort By:
Page
of 97
Circulation. Cardiovascular Quality and Outcomes
|
August 9, 2020
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events
Hironori Hara, David van Klaveren, Kuniaki Takahashi, et al.
American Heart Journal
|
March 8, 2024
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial
Mitchell Krucoff, Alessandro Spirito, Usman Baber, et al.
Archives of Cardiovascular Diseases
|
May 31, 2024
Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) study
Alexandre Gautier, Nicolas Danchin, Gregory Ducrocq, et al.
Lancet (London, England)
|
September 7, 2010
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
Shamir R Mehta, Jean-Francois Tanguay, John W Eikelboom, et al.
European Journal of Preventive Cardiology
|
July 6, 2023
Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease
Pascal M Burger, Jannick A N Dorresteijn, Aernoud T L Fiolet, et al.
The American Journal of Cardiology
|
October 26, 2019
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)
Chun Chin Chang, Ernest Spitzer, Ply Chichareon, et al.
The Lancet. Diabetes & Endocrinology
|
July 6, 2019
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K Ray, Helen M Colhoun, Michael Szarek, et al.
Journal of the American College of Cardiology
|
September 3, 2025
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants
Sean J Jurgens, Giorgio E M Melloni, Shinwan Kany, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 27, 2019
Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial
Mariusz Tomaniak, Ply Chichareon, Kuniaki Takahashi, et al.
BMJ Open
|
March 11, 2019
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)
Sergio Leonardi, Anna Franzone, Raffaele Piccolo, et al.
Page
of 97